Clinicians and investigators
in the
fields of
veterinary and human endocrine oncology, clinical trials, pathology, and
drug development will be joined
in this consortium,
in order to improve knowledge, development of, and access to naturally occurring canine endocrine tumours, as a model for human disease.
It is a growing
field in human and
veterinary medicine, and the hope of
veterinary pharmacogeneticists is to discover more about species, breed, and individual variations that put animals at risk for adverse
drug reactions.